AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
ResMed stock jumps 3.1% after beating Q4 estimates with 10% revenue growth and 23% EPS increase.
ByAinvest
Friday, Aug 1, 2025 12:45 pm ET1min read
ResMed reported Q4 revenue of $1.35bn, a 10% YoY increase, and adjusted EPS of $2.55, a 23% YoY increase, beating analyst estimates. The company attributed the strong performance to robust global demand for its sleep and breathing health devices. ResMed also announced a 13% increase in its quarterly dividend. The shares jumped 3.1% before cooling down to a 2.9% gain.
ResMed Inc. (RMD) reported a strong fourth quarter for fiscal 2025, with adjusted earnings per share (EPS) of $2.55, up 22.6% year over year (YoY), and revenue of $1.35 billion, a 10.2% YoY increase. These figures exceeded the Zacks Consensus Estimate by 3.66% and 1.87%, respectively [1].The company attributed the robust performance to high global demand for its sleep and breathing health devices. ResMed's adjusted EPS for the full year 2025 was $9.55, up 23.7% from 2024, and revenue reached $5.15 billion, a 9.8% YoY increase. The stock price rose 2.6% in after-market trading following the announcement [1].
ResMed operates through two reporting units: Sleep and Breathing Health and Residential Care Software. Sleep and Breathing Health revenues increased 10.2% YoY to $1.18 billion, while Residential Care Software revenues grew 9.9% YoY to $167 million. The company's adjusted gross profit margin expanded to 61.4% in the fourth quarter, up 227 basis points (bps) YoY [1].
ResMed also announced a 13% increase in its quarterly dividend, paying $0.37 per share. The shares initially jumped 3.1% but cooled down to a 2.9% gain. The company's cash and cash equivalents stood at $1.21 billion at the end of the quarter, up significantly from $238.4 million at the end of fiscal 2024 [1].
ResMed's Zacks Rank is currently #3 (Hold), indicating that the stock is expected to perform in line with the market in the near future. The company's earnings outlook will be closely watched by investors [2].
References:
[1] https://www.nasdaq.com/articles/resmed-q4-earnings-revenues-beat-estimates-stock-margins-climb
[2] https://www.nasdaq.com/articles/resmed-rmd-surpasses-q4-earnings-and-revenue-estimates
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet